Basis of Presentation (Details Narrative) - USD ($) |
12 Months Ended | |
|---|---|---|
Dec. 31, 2022 |
Dec. 31, 2021 |
|
| Product Information [Line Items] | ||
| Capitalized software development costs | $ 167,543 | $ 186,271 |
| Capitalized computer software, amortization | 55,847 | 0 |
| Capitalized computer software, impairments | 0 | 0 |
| Research and development expense | 190,117 | $ 90,874 |
| Operating loss carryforwards | $ 3,514,896 | |
| Net operating losses carryforwards, expire date | begin to expire in 2027 | |
| Accounts Receivable [Member] | Customer Concentration Risk [Member] | Customer One [Member] | ||
| Product Information [Line Items] | ||
| Concentration risk percentage | 32.40% | |
| Accounts Receivable [Member] | Customer Concentration Risk [Member] | Customer Two [Member] | ||
| Product Information [Line Items] | ||
| Concentration risk percentage | 10.30% | |
| X | ||||||||||
- Definition Net operating losses carryforwards expire date. No definition available.
|
| X | ||||||||||
- Definition Amount of expense for amortization of capitalized computer software costs. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of impairment loss from capitalized computer software costs. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Unamortized costs incurred for development of computer software, which is to be sold, leased or otherwise marketed, after establishing technological feasibility through to the general release of the software products. Excludes capitalized costs of developing software for internal use. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|